The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.x

Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

Separation from RA-related accelereted pulmonary fibrosis can be extremely difficult (PMID 23791462)

Publications

Schuller A, Coudurier M, Lega JC, Khouatra C, Cottin V, Cordier JF

[Interstitial lung disease and anti-TNF-alpha therapy in rheumatoid arthritis: Two different patterns?].

Revue des maladies respiratoires 2010 Mar;27;232-7 — 2010 Mar — 232-7

Allanore Y, Devos-François G, Caramella C, Boumier P, Jounieaux V, Kahan A

Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.

Annals of the rheumatic diseases 2006 Jun;65;834-5 — 2006 Jun — 834-5

Tengstrand B, Ernestam S, Engvall IL, Rydvald Y, Hafström I

[TNF blockade in rheumatoid arthritis can cause severe fibrosing alveolitis. Six case reports].

Lakartidningen 2005 Dec 5-11;102;3788-90, 3793 — 2005 Dec 5-11 — 3788-90, 3793